ArticleScientific reports2025
Platelet indicators do not influence the impact of ABO blood groups on lung adenocarcinoma susceptibility.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate the role of platelet indicators in the susceptibility of ABO blood groups to lung adenocarcinoma. This was a multicenter retrospective cohort analysis. The study included 528 patients diagnosed with primary lung adenocarcinoma and 528 randomly selected control group patients who were admitted to the Chengdu Fifth People's Hospital from January 2021 to September 2023. Additionally, it included 1452 patients diagnosed with primary lung adenocarcinoma and 1452 control group patients who were admitted to the Sichuan Cancer Hospital from November 2013 to May 2021. Platelet indicators were studied using an automated blood counter. ABO blood groups were determined by the gel column method using agglutination techniques. Statistical analysis was performed using Chi-square tests, independent-samples T-tests, ANOVA, and logistic regression. Chi-square analysis showed that there was a difference in ABO blood group composition between the lung adenocarcinoma group and the control group (p < 0.001). Independent-samples T-tests showed that MPV was significantly higher in lung adenocarcinoma than in control group (p = 0.025). The ANOVA of ABO blood groups and platelet indicators in lung adenocarcinoma showed that the average platelet count (PLT) of O group blood was higher than that of B group blood (p = 0.037), while the mean platelet volume (MPV) was significantly lower than that of A group, B group and AB group blood (p = 0.009). After adjusting for gender and age, logistic regression analysis showed that the risk of lung adenocarcinoma in blood groups O and B was higher than that in blood group A (p < 0.05 for each) and blood group AB (p < 0.05 for each), regardless of whether platelet indicators were added. Meanwhile, logistic regression showed that high platelet volume (MPV) was a risk factor for lung adenocarcinoma (p = 0.029). Our findings suggest that platelet indicators are respectively associated with ABO blood groups and lung adenocarcinoma. However, platelet indicators may not influence the ABO blood groups related susceptibility to Lung Adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.